Acura Pharmaceuticals, Inc. is a drug delivery company, which engages in the research, development, and commercialization of technologies and products intended to address safe use of medications. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Based on 7 analysts giving stock ratings to ACUR, updated on Dec 01, 2021
Buy
Strong buy
2
Buy
4
Hold
1
Sell
0
Strong sell
0
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for ACUR. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: ACUR is a Buy candidate.
ACUR stock price ended at $0 on Wednesday, after rising NaN%
On the latest trading day Jun 17, 2026, the stock price of ACUR rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 4.4K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 449 shares were traded, amounting to a market value of approximately --.
ACUR Technical Signals
Technical Signals Summary
Buy Signals 3
Neutral Signals 3
Sell Signals 1
Strong Sell
Sell
Neutral
Buy
Strong Buy
ACUR currently exhibits 3 buy signals and 1 sell signals. The stock has been in an uptrend since 12:00 AM, with a total price change of -- during this period. Overall, the technical indicators point to a Buy outlook for the mid-term.
Bullish/Bearish Signals for ACUR
Our algorithms analyze key indicators like moving averages, RSI, MACD, and trading volume to generate bullish and bearish signals for ACUR. These insights help you make informed investment decisions.
Follow-Up Questions
How do technical analysis indicators apply to ACUR?
According to technical analysis, Acura Pharmaceuticals Inc has an aggregate signal of Buy. Acura Pharmaceuticals Inc has 3 Buy signals, 3 Neutral Signals and 1 sell signals.
What are the Fibonacci retracement levels for ACUR?
The Fibonacci retracement level for Acura Pharmaceuticals Inc is between 0% and 23.6%
What is the RSI for Acura Pharmaceuticals Inc?
The RSI for Acura Pharmaceuticals Inc is currently 46.42, indicating a neutral condition
What is Acura Pharmaceuticals Inc price for the next 12 months?
Acura Pharmaceuticals Inc ACUR price for the next 12 months is estimated at $0.
How high is Acura Pharmaceuticals Inc expected to go?
According to wall street analysts, Acura Pharmaceuticals Inc is expected to reach a high forecast of $0.